Table 3. Proteins with nominal evidence for change (unadjusted p<0.05) during treatment of the protein array cohort (n=22 patients).
| A | |||||
| Protein |
Dynamics of protein level (SOM – BL) (No. of patients) |
Direction | p-value | ||
| Increased | ND | Decreased | Up/down | ||
| TIMP-1 | 17 | 0 | 5 | ↑ | 0.004 |
| PTX-3 | 16 | 0 | 6 | ↑ | 0.014 |
| IGFBP-3 | 12 | 1 | 9 | ↑ | 0.044 |
| PF-4 | 15 | 0 | 7 | ↑ | 0.046 |
| Endothelin-1 | 3 | 5 | 14 | ↓ | 0.002 |
| MMP-8 | 6 | 0 | 16 | ↓ | 0.004 |
| PDGF-ab | 2 | 1 | 19 | ↓ | 0.004 |
| PDGF-aa | 5 | 0 | 17 | ↓ | 0.006 |
| Angiopoietin-1 | 3 | 0 | 19 | ↓ | 0.006 |
| EGF | 3 | 6 | 13 | ↓ | 0.006 |
| Hb-EGF | 2 | 6 | 14 | ↓ | 0.009 |
| TIMP-4 | 7 | 0 | 15 | ↓ | 0.046 |
| B | |||||
| Protein |
Dynamics of protein level (EOT – SOM) (No. of patients) |
Direction | p-value | ||
| Increased | ND | Decreased | Up/down | ||
| TIMP-4 | 16 | 0 | 6 | ↑ | 0.007 |
| MMP-8 | 17 | 0 | 5 | ↑ | 0.019 |
| EGF | 7 | 14 | 1 | ↑ | 0.034 |
| Amphiregulin | 4 | 18 | 0 | ↑ | 0.046 |
| Tissue factor | 4 | 18 | 0 | ↑ | 0.046 |
| Cd26 | 7 | 0 | 15 | ↓ | 0.017 |
3A. Changes from baseline (BL) to start of maintenance (SOM); Chemotherapy + Bevacizumab treatment. 3B. Changes from start of maintenance (SOM) to End of Treatment (EOT); Bevacizumab treatment. ND= non-detectable serum protein levels.